Benefit From OTC Switches Supported In Study Of PPIs' Outpatient Impact
Executive Summary
Proton pump inhibitor OTC switches since 2003 had a profound and sustained impact on outpatient health care visits – illustrating the potential for other switches to benefit US health care, a recent study suggests.
You may also be interested in...
Private Label Competition For Zegerid OTC Sets Sail With Perrigo Launch
Perrigo's omeprazole and sodium bicarbonate capsules indicated for the treatment of frequent heartburn will bear labeling that has been through several updates since the first PPI became available OTC in 2004.
Merck Silence On OTC Singulair Speaks Volumes On Switch Outlook
Merck’s silence on an OTC version of Singulair is a sign of the relatively “quiet” 2015 switch market despite the call for novel switches, particularly to treat chronic conditions, from FDA’s Nonprescription Drug Safe Use Regulatory Expansion Initiative.
CAGR For OTC Switch Forecast At 5%, But Without Statins, Asthma Treatments
OTC switch product sales are estimated to grow at a compounded annual growth rate of 5% by 2019, with opportunities likely emerging in bladder control for women and sleep aids, according to Kline Market Research. But asthma drugs and statins are not likely to debut OTC soon, notes analyst Laura Mahecha.